Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to$ 370 - $390 million –– Abiprubart Phase 2b trial in Sjögren's Disease planned to initiate in 2H 2024 –– Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, April 23, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KN ...